BridgeBio Pharma, Inc. (NASDAQ: BBIO) disclosed that its Chief Accounting Officer, Maricel Apuli, executed two equity transactions in mid-February 2026.
According to a Form 4 filed with the Securities and Exchange Commission, Apuli sold 510 shares of common stock on February 17, 2026 at a price of $74.31 per share, for aggregate proceeds of $37898. The filing also shows that Apuli had 4,349 shares withheld on February 16, 2026 to satisfy tax obligations; those shares were withheld at a price of $75.25 per share, representing $327262.
Following these moves, the filing reports that Apuli directly holds 123945 shares of BridgeBio common stock.
Separately, BridgeBio announced clinical and financing developments that have drawn investor attention. The company reported positive Phase 3 results from the PROPEL 3 trial of oral infigratinib for the treatment of achondroplasia. The trial met its primary endpoint, demonstrating a superior annualized height velocity versus placebo with a mean treatment difference of +2.10 cm/year. The company also reported that the study achieved the first statistically significant improvement in body proportionality in a randomized achondroplasia trial.
Market participants and sell-side analysts reacted to the clinical readout. Raymond James raised its price target for BridgeBio to $89 and maintained an Outperform rating. Barclays initiated coverage with an Overweight rating and set an $80 price target, citing BridgeBio’s diversified late-stage portfolio.
On the financing front, BridgeBio priced a private offering of $550 million aggregate principal amount of convertible senior notes due in 2033. The notes carry an interest rate of 0.75% and include a conversion premium of 45%.
Taken together, the insider transactions, the Phase 3 readout for infigratinib, analyst actions, and the convertible note offering constitute the material disclosures captured in the recent filings and company statements.
Summary of filings and disclosures
- Apuli sold 510 shares on February 17, 2026 at $74.31, totaling $37898.
- Apuli had 4,349 shares withheld on February 16, 2026 at $75.25, totaling $327262, to cover tax obligations.
- Apuli now directly owns 123945 shares of BridgeBio common stock.
- BridgeBio reported positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia - primary endpoint met, mean treatment difference +2.10 cm/year, and a first statistically significant improvement in body proportionality in a randomized achondroplasia trial.
- Raymond James raised its price target to $89 and kept an Outperform rating; Barclays started coverage with an Overweight rating and an $80 target.
- BridgeBio priced $550 million of convertible senior notes due 2033, at 0.75% interest and with a 45% conversion premium.